on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has submitted a Form 8.3 disclosure under the Irish Takeover Panel Act, revealing its interests in Avadel Pharmaceuticals plc. According to the form, The Vanguard Group holds 5,565,939 ordinary shares, representing a 5.71% stake in Avadel Pharmaceuticals.
The announcement was made on November 24, 2025, detailing an opening position disclosure recorded on November 21, 2025. No additional parties to the offer were disclosed, and no cash-settled or stock-settled derivatives were reported.
The filing specifies that there are no indemnity or option arrangements related to the relevant securities. Furthermore, The Vanguard Group confirms the absence of agreements or arrangements associated with voting rights or future transactions of the securities mentioned.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news